TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01517828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedation by ketamine
Description: Kétamine (50mg/5ml, Panpharma): for a posology of 2 mg/kg: dose of 0.2 ml/kg Intranasal administration with a 1 ml syringe. Kétamine is a derivated of phencyclidine with a sedative, anesthesic, analgesic and amnesiant activity. Ketamine keeps also a protective reflex of upper respiratory tracts.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedation with Midazolam
Description: Midazolam (phyal of 5mg/5ml, Mylan S.A.S.) for a posology of 0.2 mg/kg: dose of 0.2 ml/kg Instillation in intranasal with a syringe of 1 ml. Midazolam is an imidazobenzodiazépine, witj a sedative and hypnotic activity,anxiolytic, anti convulsive and muscle relaxant proprieties.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done.
Study: NCT02949713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging-motivational interviewing
Description: Interactive weekly mobile phone text messaging plus prospective motivational interviews
Study: NCT00977587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces Cerevisiae CNCM I-3856
Description: Saccharomyces cerevisiae CNCM I-3856, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).subjects will take 1 capsule twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo: Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:~* Calcium phosphate, Dibasic 472.0 mg~* Maltodextrin DE14 112.1 mg~* Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day
Study: NCT02408926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix
Description: Pregnant women will be vaccinated with an acellular pertussis containing vaccine between 27 and 36 weeks of gestation.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: Pregnant women will be vaccinated with an acellular pertussis containing vaccine between 27 and 36 weeks of gestation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Children from group A will be vaccinated with an acellular pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quinvaxem
Description: Children from group B will be vaccinated with a whole cell pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OPV
Description: Children from group B will be vaccinated with OPV vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
Study: NCT03423563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible fiberoptic bronchoscopy
Description: Flexible fiberoptic bronchoscopy versus flexible intubation video endoscope regarding intubation time in obese patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fexible intubation video endoscopy
Description: Fexible intubation video endoscopy
Study: NCT04628598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antenatal care and prenatal education with a home visit
Description: Providing prenatal education and care by home visits to pregnant women
Study: NCT01927068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stellarex 0.035 Over-the-Wire (OTW) drug-coated angioplasty balloon (Stellarex DCB)
Description: Percutaneous Transluminal Angioplasty will be completed using a 2.0 micrograms per square millimeter. Paclitaxel-Coated Balloon. Balloon will be inflated to a size appropriate for the target vessel, as determined by the physician. Total balloon inflation time is determined by the physician, but no less than one minute.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stellarex 0.035 Over-the-Wire (OTW) drug-coated angioplasty balloon (Stellarex DCB)
Description: Percutaneous Transluminal Angioplasty will be completed using a 2.0 micrograms per square millimeter. Paclitaxel-Coated Balloon. Balloon will be inflated to a size appropriate for the target vessel, as determined by the physician. Total balloon inflation time is determined by the physician, but no less than one minute.
Study: NCT00044213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EDTA
Description: Participants will receive 40 infusions of standard chelation solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EDTA
Description: Participants will receive 40 infusions of standard chelation solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EDTA Placebo
Description: Participants will receive 40 infusions of EDTA placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EDTA Placebo
Description: Participants will receive 40 infusions of EDTA placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Vitamin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High Dose Vitamin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High Dose Vitamin Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High Dose Vitamin Placebo
Study: NCT04555408

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: blue light
Description: Patients receive exposure to 100lux blue light, which dominant wave-length is 468nm for 30 minutes in the morning.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bright light
Description: Patients receive exposure to 1000lux bright light, which dominant wave-length is 490nm for 30 minutes in the morning.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: dim light
Description: Patients receive exposure to 100lux dim light, which dominant wave-length is 490nm for 30 minutes in the morning.
Study: NCT03895918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: Undergo parenting skills intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: Undergo parenting skills intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: Undergo parenting skills intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient Monitoring
Description: Undergo medication adherence monitoring

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient Monitoring
Description: Undergo medication adherence monitoring

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient Monitoring
Description: Undergo medication adherence monitoring

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01762527

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy
Description: CTCAE scoring baseline, every 2'nd week during RT, 2 weeks, 3, 12 and 24 month after RT cineMR (time resolved MR) baseline and weekly during RT for intra fractional motion
Study: NCT03299452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non Chemotherapy
Description: Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy and target therapy
Description: Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herb medicine
Description: Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
Study: NCT02527564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00493441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVN944
Description: 150, 200, 250, 300, or 400 mg q12h
Study: NCT01952093

Intervention type: BEHAVIORAL
Intervention: Home-based intervention program
Description: The intervention had been done in the previous intervention study. The intervention included in-hospital and after-discharge service. After-discharge intervention performed at 0, 1, 2, 4, 6, 9, 12 months of age at the home.

Intervention type: BEHAVIORAL
Intervention: Clinic-based intervention program
Description: The intervention had been done in the previous intervention study. The intervention included in-hospital and after-discharge service. After-discharge intervention performed at 0, 1, 2, 4, 6, 9, 12 months of age at the clinic.
Study: NCT02060968

Intervention type: DEVICE
Intervention: Promus PREMIER
Study: NCT01505660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care management
Description: The intervention will include healthcare delivery team notification of patient reported outcomes (PROs) including medication adherence and adherence barriers such as depression symptoms along with intervention recommendations and targeted care management using a stepped care approach. Patients will receive structured calls from their care manager 2 and 6 weeks after enrollment. An assessment including depression, adherence, and substance use will be completed at the beginning of each call. After the 2nd call, a stepped care approach will be used where patients with a greater need based on adherence and depression will receive more intensive interventions based on the PEARL intervention. The components include: a) problem solving treatment, b) social and physical activation, c) pleasant events scheduling, d) patient support and education regarding medication use, and e) medical and psychiatric consultation. Patients will also receive follow-up calls at \~9 and 12 months after enrollment.
Study: NCT03771677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2A
Description: Peginterferon alfa-2a 180ug per week
Study: NCT02198560

Intervention type: DEVICE
Intervention: RS-3000 Lite
Study: NCT04633031

Intervention type: DEVICE
Intervention: Boston

Intervention type: DEVICE
Intervention: Cheneau
Study: NCT03683043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long GnRH agonist protocol
Description: 8. The patients follow long protocol, which includes down regulation starting on day 21 of the previous cycle. The patient is seen after 14 days to confirm down regulation. Serum E2 ≤ 50 pg/ mL and no ovarian cysts observed in transvaginal US.~9. Induction is started on day 3 of the current cycle by gonadotrophins (FSH and LH) daily IM or SC injections provided that the different preparations at the market can be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long GnRH agonist protocol
Description: 8. The patients follow long protocol, which includes down regulation starting on day 21 of the previous cycle. The patient is seen after 14 days to confirm down regulation. Serum E2 ≤ 50 pg/ mL and no ovarian cysts observed in transvaginal US.~9. Induction is started on day 3 of the current cycle by gonadotrophins (FSH and LH) daily IM or SC injections provided that the different preparations at the market can be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Cusco speculum was used to allow access to the cervix. The vagina was flushed by saline, and the cervical mucus is removed by Q-tips and/ or suction tubes. In few cases, where patients had long vaginae; two Sims' speculums were used to spread the vaginal anterior and posterior vaginal walls apart. In these cases, the attending nurse assisted the gynecologists during transfer The gynecologist asks the embryologist to load the embryos in the transfer catheter, and the gynecologist receives the loaded catheter from a window connecting the lab and operating room. In cases of trans-vaginal ultrasound guided embryo transfer the embryologist hands in the catheter to the gynecologists in the outer sheath and the gynecologist injects slowly the fluid containing the embryo/s. All patients are asked to rest for 30 minutes after the transfer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Cusco speculum was used to allow access to the cervix. The vagina was flushed by saline, and the cervical mucus is removed by Q-tips and/ or suction tubes. In few cases, where patients had long vaginae; two Sims' speculums were used to spread the vaginal anterior and posterior vaginal walls apart. In these cases, the attending nurse assisted the gynecologists during transfer The gynecologist asks the embryologist to load the embryos in the transfer catheter, and the gynecologist receives the loaded catheter from a window connecting the lab and operating room. In cases of trans-vaginal ultrasound guided embryo transfer the embryologist hands in the catheter to the gynecologists in the outer sheath and the gynecologist injects slowly the fluid containing the embryo/s. All patients are asked to rest for 30 minutes after the transfer
Study: NCT02837809

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose CT
Description: annual CT vs biennial CT
Study: NCT02699671

Intervention type: DEVICE
Intervention: Bioresorbable Vascular Scaffold
Study: NCT00995267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent-child interaction/activities based on Adler's methods
Description: Description of the Intervention:~5 joint classroom activities (parents and children together, involving children in food choices/food preparation-sense of belonging/decision making): 1. Healthy breakfasts and 10 o'clock snacks 2. Fats and oils in the diet, cooking methods, setting limits to oily food intake. 3. Fruit and vegetables in the daily diet, adults as role models. 4. Learning about food categories \& pyramid, healthy eating and growth. 5. Limiting consumption of sweets and snacks.~Workshop for Parents: Explaining nutritional needs of children; how to encourage good eating habits, how to deal with children's manipulations, providing tools to elicit change; use of food to attract parental attention; practical tools to deal with their children's eating habits/obesity/refusal to eat/chronic health problems/failure to grow; ways to prevent use of food as an answer to childhood frustrations.
Study: NCT03199144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 3 cycles of Gemzar-Abraxane

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Stereotactic radiation treatment delivering 30 Gy in 5 fractions over 9 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Whipple procedure will be the recommended procedure but will be modified according to the initial tumor location
Study: NCT01922739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER
Description: Participants were instructed to take hydrocodone ER tablets orally with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: During the double-blind titration period used in the original protocol, placebo tablets matching each dose of hydrocodone bitartrate ER tablets (active drug) were used to maintain the blind but not for purposes of comparison.
Study: NCT00107172

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Study: NCT01038089

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol
Study: NCT03389269

Intervention type: OTHER
Intervention: Meal test
Description: 240 min mixed meal test with aspiration using AspireAssist.

Intervention type: OTHER
Intervention: Meal test
Description: 240 min mixed meal test with aspiration using AspireAssist.
Study: NCT03529851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly questionnaires
Description: In case of alarming symptoms reported in the questionnaire, an alert is automatically sent to the hospital. The clinicians will contact the patient, confirm the symptoms and intervene according to standard practice.
Study: NCT03949361

Intervention type: DIAGNOSTIC_TEST
Intervention: Indirect calorimetry
Description: Resting energy expenditure
Study: NCT03736551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5:2 diet
Description: very low energy diet (600 kcal/day) on 2 consecutive days of the week, and 5 days each week on an energy restricted diet to maintain a similar overall energy deficit of 600 kcal/day across the week (5:2 diet)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Renal Weight Management Programme
Description: Dietary intervention includes a standard continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day relative to their estimated total energy expenditure. In addition to the dietary intervention, the programme also includes personal exercise plans, optional pharmacotherapy (orlistat at standard dose), and development of personalised dietary and exercise goals using behavioural therapy techniques and motivational interviewing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Renal Weight Management Programme
Description: Dietary intervention includes a standard continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day relative to their estimated total energy expenditure. In addition to the dietary intervention, the programme also includes personal exercise plans, optional pharmacotherapy (orlistat at standard dose), and development of personalised dietary and exercise goals using behavioural therapy techniques and motivational interviewing.
Study: NCT01519349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV1.CMV.huFollistatin344
Description: * First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)~* Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)~* Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV1.CMV.huFollistatin344
Description: * First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)~* Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)~* Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV1.CMV.huFollistatin344
Description: * First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)~* Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)~* Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)
Study: NCT05270083

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NeuraCeq PET imaging with intravenous (IV) dose of 300MBq of Neuraceq™ ([F-18]Florbetaben)
Description: Participants will receive an intravenous (IV) dose of 300 MBq of Neuraceq™ in a volume of 10 mL or less. A 30 minute duration PET image will be acquired starting immediately after Neuraceq™ injection. A second 20-minute duration PET image will be acquired starting 90 minutes after Neuraceq™ injection.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NeuraCeq PET imaging with intravenous (IV) dose of 300MBq of Neuraceq™ ([F-18]Florbetaben)
Description: Participants will receive an intravenous (IV) dose of 300 MBq of Neuraceq™ in a volume of 10 mL or less. A 30 minute duration PET image will be acquired starting immediately after Neuraceq™ injection. A second 20-minute duration PET image will be acquired starting 90 minutes after Neuraceq™ injection.
Study: NCT03051269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium chloride
Description: Tumour site is injected with a solution of 9 mg/ml calcium chloride and afterwards the tumour site is given electroporation to facilitate calcium to enter the cell cytosol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroporation
Description: Performed by single use electrodes attaches to a device called Cliniporator provided from IGEA, ITALY.
Study: NCT00187044

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PolyEnv1 vaccine
Description: administered subcutaneously as 10\*7 pfu in 0.8 mL
Study: NCT03949361

Intervention type: DIAGNOSTIC_TEST
Intervention: Indirect calorimetry
Description: Resting energy expenditure

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Temperature
Description: Temperature: supraclavicular, infraclavicular, abdominal, mid-thigh, non-dominant lower arm, middle finger tip, left lower leg, left dorsal foot, ear thermometer

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Temperature
Description: Temperature: supraclavicular, infraclavicular, abdominal, mid-thigh, non-dominant lower arm, middle finger tip, left lower leg, left dorsal foot, ear thermometer

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual energy X-ray Absorptiometry (DXA)
Description: Body composition

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual energy X-ray Absorptiometry (DXA)
Description: Body composition

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sampling
Description: thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), HbA1c, Fibroblast growth factor 21 (FGF21)

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sampling
Description: thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), HbA1c, Fibroblast growth factor 21 (FGF21)

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG-PET
Description: Dynamic PET scanning of the neck-region
Study: NCT03419507

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube introducer
Description: The doctors that drawed envelop number 2 will be asked to intubate with laryngoscope by the adult size, endotracheal tube introducer with using No. 3 Macintosh blade

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscopy
Description: The doctors who drawed envelope number 1 will asked to intubate with using No. 3 Macintosh blade
Study: NCT01341782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maxacalcitol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paricalcitol placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maxacalcitol placebo